Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 8 of the 112 sources its claims cite were checked for support.
Abstract
Introduction: The availability and affordability of safe, effective, accessible, and high-quality essential medicines is a critical benchmark for achieving the right to good health, and it is also one of the goals of the global health development agenda. To that end, it is critical to conduct rigorous studies to identify the major challenges confronting developing countries, particularly those in Africa. Objective: The purpose of this review was to identify the major challenges that Africans face in obtaining reasonably priced and readily available essential medicines. Methods: Generally the Boolean operators "AND" and "OR" were employed. Making progress also involves using duplicate checks, field definitions, and comparisons of articles and criteria. The analysis included all English-language papers published in any African country between 2005 and 2022, depending on the year of publication. The technique searches electronic databases for key phrases related to essential medication availability and affordability, such as PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar. Results: A total of 91 articles; by using search engines and handpicking including duplicates, were primarily searched. The electronic database search earned 78 articles while only eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries. Inadequate human resources, financial constraints, high cost of available medications on the market, poor inventory management, manual consumption forecasting, inefficiencies in drug registration, and trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations. Conclusion: This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges. The primary challenge, according to the review research, is a lack of adequate financing to pay for an appropriate set of essential medications, which account for a significant portion of household spending.
Overview
CoChat Summary
TL;DR
This scoping review synthesizes 11 studies on barriers to essential medicine availability and affordability in African countries, identifying financing, pricing, supply-chain, human-resource, regulatory, and governance challenges. It concludes that availability remains below the WHO 80% benchmark and that medicines are often unaffordable, especially for poor households.
Key findings
- The review included 11 studies: 5 qualitative, 4 cross-sectional, and 2 mixed; 5 (50%) were from East African countries. Reported barriers included inadequate human resources, financial constraints, high market prices, poor inventory management, manual consumption forecasting, inefficient drug registration, and TRIPS-related regulations.
- Availability was low: in one 8-country survey of 3,353 hospitals and primary care facilities, mean availability of 12 essential medicines ranged from 22% to 40%; in Uganda, average availability of tracer drugs in public pharmacies was 63.3%; in South Africa, public-sector median availability of lowest-price brands and generics was 10% and 75%, while private-sector median availability was 28.6%.
- Affordability was poor: high-cost essential medicines required the lowest-paid government employee to work 15 days for a one-month supply; branded medicines were 13.8 times more expensive than generics, and generics and brands were purchased at 2.9 and 32.6 times international reference prices, respectively. In Ethiopia, 45.6% of non-buyers cited unavailability, 45.7% cited expense, 8.7% cited ineffectiveness, and 11.8% forwent treatment due to cost.
- The review reports that African-region median availability of essential medicines was 61.5% versus 27.3% for nonessential medicines; public-sector median availability was 40% and private-sector 78.1%, compared with 6.6% and 57.1% for nonessential medicines. The conclusion states availability does not exceed 65% and purchasing costs are unaffordable.
Methods
- Scoping review searching PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar, using Boolean operators “AND” and “OR,” field specifications, duplicate checks, and article/criteria comparisons.
- Inclusion covered English-language, open-access PDF articles on challenges to essential medicine availability, affordability, and accessibility in African countries; the abstract and inclusion criteria state 2005–2022, while the search strategy states 2005–2023. Dissertations, abstracts, editorials, clinical views, non-African studies, and abstract-only publications were excluded.
- Methodological quality was assessed with PRISMA and an EBL critical appraisal tool; three reviewers independently assessed full texts, with 85.7% inter-observer agreement. Validity thresholds were <75% low quality, 75–90% moderate, and >90% high; most included studies were medium reliability, with 2 (20%) rated excellent.
Limitations
- Stated by the paper: the review does not examine one influencing factor in detail or all influencing factors, but analyzes factors frequently mentioned in the reviewed articles; it also does not assess challenges across the continent as a whole and ignores national economies, policies, and regulations affecting availability and affordability.
- Evident from the text: the search and inclusion numbers are inconsistent—the abstract reports 91 articles primarily searched and 78 from electronic databases, while the Results section reports 88 studies initially retrieved and 11 reviewed—and the date range is reported as both 2005–2022 and 2005–2023.
- Evident from the text: only 11 studies were included, most were hospital-based, 5 (50%) were from East African countries, and most were rated medium reliability, limiting continent-wide generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 4 Not valid · 80 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Transportation is widely acknowledged as a challenge in obtaining pharmaceutical care due to road closures, poor road construction, and transportation shortages; however, it is underexplored in terms of the clarity needed for tackling more immediate health and transportation policy interventions.27,28”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Transportation
What the sources say
- Partly supportedcites [27] Chandani, 2012, Am J Trop Med Hyg sourceExperimental — accuracy not yet measured
The Results section, “Precondition 4: Availability of appropriate transportation” (page unavailable), reports that community health workers identified unavailable or unreliable transport, distance, and rainy-season travel as obstacles to obtaining medicines. It notes dirt roads but does not identify road closures or poor road construction as causes. The evidence also concerns workers collecting medicine supplies, rather than patients obtaining pharmaceutical care generally. (LLM, conf=0.86)
- Not checked yetcites [28] Kanda, 2015, Int J Acad Res Account Financ Mang Sci source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Drug Registration and Regulation
What the sources say
- Not checked yetcites [36] Kefale B. Explore the challenge in medicines registration process in Ethiopia: qualitative phenomenological study; 2020.
- Partly supportedcites [38] Moran, 2011, PLoS Med sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) supports the general framing: a 2010 WHO study found 90% of sub-Saharan African MRAs 'in a situation which did not allow them to adequately carry out regulatory functions,' and 'growth in African regulatory capacity is not keeping up with these new challenges' posed by the growing demand to assess novel ND products. The Discussion likewise calls the current system inefficient and resource-wasteful, and the proposals list joint good manufacturing practices plant inspections and joint dossier review. But no passage in our copy — searched for 'quality testing procedures', 'quality control laboratories', 'batch release/testing' — identifies quality testing procedures as a registration challenge that failed to keep pace with demand; that specific element of the citing sentence is not attributable to this paper. (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low investment in essential medicines for health, a lack of comprehensive health financing policies and strategic plans, extensive out-of-pocket payments, a lack of social safety nets to protect the poor, poor financial management, inefficient resource allocation and use, and weak mechanisms for coordinating partner support constrain health financing in the African region.30,41”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > DovePress 453
What the sources say
- Could not verifycites [30] Droti, 2019, BMJ Glob Heal sourceExperimental — accuracy not yet measured
The Discussion says the surveyed countries had very limited public-sector budgets for medicine procurement, but it does not identify poor financial management as a constraint on health financing. Searches for financial management and resource allocation found no passage addressing that point. (LLM, conf=0.72)
- Supportedcites [41] Kirigia, 2008, BioMed Cent source
The Challenges section explicitly lists weak financial management among the characteristics of health financing in the African Region. That supports the attributed claim that poor financial management constrains health financing there. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
56 more claims
Create a free account to see all 123 claims and to verify the 104 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 38
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
“The electronic database search earned 78 articles”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Results
“the preliminary information retrieval system across all databases resulted in 88 studies (68 from Pub Med).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
Reported 50 · recomputed 45.454545
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“the majority of studies were of medium reliability, with 2 (20%) being of excellent quality.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > The Listed Studies' Methodological Quality
Reported 20 · recomputed 18.181818
Citations
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928 · cited 2×
“Medicines consume up to 20–60% of health expenditure in developed and transitional countries, and in developing African nations, nearly 90% of the population buys medicines out of pocket, making medicines the second-largest item of family spending after food.(32) Over 50 price and affordability surveys were conducted…”
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661 · cited 3×
“To be available and affordable drugs should be used in a suitable, safe, cost-effective, secure, and accessible way.(7) Given that from 2001 to 2007, just 30% of all both private and public health facilities in African countries had access to vital medicines, more than 70% of the population in Africa was impacted.”
InfluentialMendis, S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.033647 · Cited by 487 · cited 3×
“The World Health Organization and Health Action International recommend using the LPGW’s income as a benchmark for comparing the cost of medication care to the availability of medications.(2,20) Since the current global minimum salary is US $ per day, the lowest-paid unskilled government employee’s daily wage will be…”
InfluentialA critical appraisal tool for library and information research
Glynn, L. (2006) · Library Hi Tech · doi:10.1108/07378830610692154 · Cited by 345 · cited 2×
“The calculation for overall validity was: (Y+N +U=T); If Y/T ≥75% or if N+U/T ≤ 25% then it can safely conclude that the study is valid.(23) A score of less than 75% was considered low quality, 75% to 90% was considered moderate quality, and more than 90% was considered high quality.”
Modisakeng, C., Matlala, M., Godman, B., & Meyer, J. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05080-1 · Cited by 130 · cited 2×
“According to the World Bank, approximately 80% of the African continent’s population, primarily those in the middle and lower income brackets, rely on public health facilities to access health care.(25) Several factors have been linked to affecting the accessibility of essential medicines in Africa’s public and privat…”
Revisiting the issue of access to medicines in Africa: Challenges and recommendations
Adebisi, Y. A., Nwogu, I. B., Alaran, A. J., Badmos, A. O., Bamgboye, A. O., Rufai, B. O., Okonji, O. C., Malik, M. O., Teibo, J. O., Abdalla, S. F., et al. (2022) · Public Health Challenges · doi:10.1002/puh2.9 · Cited by 111 · cited 6×
“Many people living in Africa have a problem with accessing medicines and this undoubtedly contributes to the poor health metrics of most countries in the region.(4) The availability and cost of medications are considered two of the most crucial factors for providing healthcare users with quality healthcare, along with…”
InfluentialHealth challenges in Africa and the way forward
Kirigia, J., & Barry, S. (2008) · International Archives of Medicine · doi:10.1186/1755-7682-1-27 · Cited by 110 · cited 4×
“Extreme shortages of highly qualified health professionals, rooted in African countries, have been exacerbated by disparities in labor distribution and brain drain in this crisis, jeopardizing the delivery of effective public health interventions to those in need, particularly in remote rural areas.(16,41) Professiona…”
InfluentialMajor Public Health Problems in Nigeria: A review
Muhammad, F., Abdulkareem, J. H., & Chowdhury, A. A. (2017) · South East Asia Journal of Public Health · doi:10.3329/seajph.v7i1.34672 · Cited by 79 · cited 1×
“43”
Chandani, Y., Noel, M., Pomeroy, A., Andersson, S., Pahl, M. K., & Williams, T. (2012) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2012.11-0781 · Cited by 74 · cited 1×
“27,28 Outlined that transportation infrastructure affects the total supply chain performance of pharmaceuticals due to poor infrastructure construction, development, heavy traffic over-crowding in large cities, and poor availability in rural areas of Africa.”
Research works printed but not linked: 16
- World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies WHO Guideline on Country Pharmaceutical Pricing Policies. World Health Organization; 2020:1–70.
- Bruno, 2015, J Pharm Care Heal Syst, 1, 10.4172/jpchs.s2-006 · doi:10.4172/jpchs.s2-006
- Latifah, 2019, Rev Artic, 10, 67
- Fredrick, 2016, IOSR J Business Manag, 18, 63, 10.9790/487x-1810066375 · doi:10.9790/487x-1810066375
- Obuaku, 2014, Afr Soc Rev, 18, 42
- Zuma, 2019, World J Pharm Res, 8, 1532, 10.20959/wjpr20199-15303 · doi:10.20959/wjpr20199-15303
- Abiye, 2013, J Appl Pharma Sci, 3, 101, 10.7324/japs.2013.31017 · doi:10.7324/japs.2013.31017
- Irene, 2016, J Health Med Nurs, 27, 45
- Mendis, 2007, Lancet, 85, 279, 10.2471/blt · doi:10.2471/blt
- World Health Organization. Measuring affordability and price availability, components. In: Medicine Prices, Measuring Affordability and Price Availability, Components. World Health Organization; 2008:1–310.
- Machemedze MMR, Munyuki E. Literature review on bottlenecks to essential medicines production and procurement in East and Southern Africa; 2013:1–23.
- Modisakeng, 2020, MBC Heal Serv Res, 1, 1
- Osei-Assibey, 2017, J Biomed Pharm Res, 6, 100
- 2019, Ensuring Access to Medicines in East Africa: Lessons from India
- Baker, 2009, Am Med Assoc J Ethics, 2009, 527
- Mohammadshahi, 2019, Shiraz E Medical J, 20, 1, 10.5812/semj.87079.review · doi:10.5812/semj.87079.review
Cited by
Items 101–200 of 220
Challenges in pediatric medicine access in Albania: insights from community Pharmacists
Petro, E., Martopullo, T., Mantel-Teeuwisse, A. K., van den Ham, H. A., & Suleman, F. (2025) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2025.2521425 · Cited by 1
Ogbodu, O. M. (2025) · International Journal of Innovative Research and Scientific Studies · doi:10.53894/ijirss.v8i5.8760 · Cited by 1
Attia-Konan, A. R., Koffi, K., Alla, E. A. H., Sindé, A. J. M., & Sackou-Kouakou, J. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s548459 · Cited by 1
“19 In Africa, several studies have revealed that drug prices are high, 22,23 compared with international reference prices 23–25 as observed in this work.”
Nang, F. D. N., Kuate, L. M., Dzudié, A., Nembot, F. D., Chebo, P. J., Fankoua, L. B., Kengne, A. P., Tchitetchoun, J. P. J., Akoa, F. A. O., Ifoue, R. M., et al. (2025) · International Journal of Public Health · doi:10.3389/ijph.2025.1608521 · Cited by 2
“Commonly reported barriers include the limited availability of antihypertensive medications [71], the lack of integrated treatment algorithms within HIV services [72], insuf fi cient healthcare worker training on NCD management [73], and the absence of dedicated funding for integrated care models…”
Literature Review: Evaluation of Drug Logistics Management Implementation
Wasni, W., Shadiqi, M. A., RAHMAN, F., Adhani, R., & Isa, M. F. M. (2025) · Indonesian Journal of Global Health Research · doi:10.37287/ijghr.v7i6.1248 · Cited by 1
“The WHO sets a minimum standard of 80% to ensure adequate access, but cross-country data shows that the average drug availability in public facilities is only around 70% (Yenet et al., 2023).”
Reuben, W., Nyondo, G. G., Sangeda, R. Z., & Ngoma, S. J. (2026) · SSM - Health Systems · doi:10.1016/j.ssmhs.2026.100183 · Cited by 1
Artemisinin-based combination therapies in Africa: efficacy, adherence, and future directions
Obeagu, E. I., Abdulrahman, A. O., & Anetor, J. I. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004773 · Cited by 2
Alemayehu, T. T., Geremew, G. W., Bekalu, A. F., Abebe, T. B., Bayleyegn, Z. W., Bekele, A., Wassie, Y. A., Tadesse, S. H., Beshada, M. A., Feye, N. T., et al. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100730 · Cited by 2
Ndwandwe, M. M., Lowane, M. P., Simbeni, T. V., & Mokgatle, M. M. (2026) · Healthcare · doi:10.3390/healthcare14050683 · Cited by 1
Gasangwa, M. A., Rukundo, J., Gashugi, Y., & Byiringiro, L. B. (2026) · Rwanda public health bulletin. · doi:10.4314/rphb.v7i1.1 · Cited by 1
Action for Access: Equity for Children With Disabilities in Lowand Middle-Income Countries
Flynn, E. C., McHenry, M. S., Kigen, B., Kapeller-Libermann, D., Fernandez, J. D. C., & Rule, A. R. L. (2026) · Pediatric Annals · doi:10.3928/19382359-20260317-03 · Cited by 1
Wuresah, I., Brooks, A. D., Kubal, N., Gold, M., Krolewiecki, A. J., & Jacobson, J. (2026) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0014458 · Cited by 1
“Ironically, poorer countries may pay higher prices proportionally, facing greater affordability challenges [48].”
Chapman, K., Rueda, S. T., Metzler, M., Holt, B. Y., Kahn-Woods, E., Thornton, D., & Gomez, G. B. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2024.1272950 · Cited by 1
La ética y la medicina familiar
Toro, O. O.-D., & Tamayo-Gómez, M. E. (2024) · Archives of Evidence-Based Medicine · doi:10.59706/aebmedicine.v2i1.9631 · Cited by 1
Uzomba, G. C., Ezemagu, U. K., Ofoegbu, M.-S., Lydia, N., Goodness, E., Emelike, C. U., Uchewa, O. O., Nwafor, A. J., & Mbajiorgu, E. F. (2024) · Anatomy & Cell Biology · doi:10.5115/acb.24.054 · Cited by 3
“Although, recent studies emphasized treatment using resistant antibodies [4], it is cost intensive, and often, the diagnostic kits are unavailable in many healthcare facilities in Nigeria and probably in other economically negatively challenged African nations [5].”
BackgroundOptimizing Health Supply Chains in LMICs with Machine Learning: A Case Study in Sierra Leone
Bastani, H., Bastani, O., & Chung, T.-H. (2024) · Springer series in supply chain management · doi:10.1007/978-3-031-60867-4_12 · Cited by 3
Ageing Population in Macao: Policies and Issues
Choy, R. (2024) · Springer eBooks · doi:10.1007/978-981-95-2175-3_7 · Cited by 1
Challenges and opportunities of AAM’s (Ayushman Arogya Mandir) in mitigating healthcare disparities
Garg, R. K., Garg, P., Bala, J., Subashini, S. P., Jasline, M., Viji, M., Mudhol, B., & Murthy, V. (2024) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_699_24 · Cited by 1
Aligning intellectual property protection with public health to ensure access to medicines in BhutanPreprint
Tshering, T., & Tshering, D. (2026) · Research Square · doi:10.21203/rs.3.rs-8597770/v1 · Cited by 1
Evaluation of Antibiotic Planning in the UNS Hospital Pharmacy Installation in 2021
Zulpadly, M. F., & Syarofina, N. (2023) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v6i4.4944 · Cited by 1
“In many developing countries, drug spending in hospitals is quite large, which can absorb around 40-50% of the hospital budget, so effective and efficient management is needed 3,4 .”
BackgroundThe Accessibility, Affordability, and Early Detection of Tuberculosis
Kadiri, T., Wilwohl, K., Torremocha, V., & Kethar, J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i2.6822
Mayntz, S. P., & Peronard, R. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100323
“These factors can significantly impact prescription rates and should have been addressed more comprehensively in the analysis [5].”
An Adapted Convolutional Neural Network for Brain Tumor Detection
Hamidja, K. B., Koffi, K., Brou, P., Asseu, O., & Oumtanaga, S. (2024) · Open Journal of Applied Sciences · doi:10.4236/ojapps.2024.1410184 · Cited by 1
Duut, B. (2024) · Ghana Pharmaceutical Journal · doi:10.38159/gpj.2024101
Kommey, B., Klogo, G. S., Paha, L. A., Yeboah, O. S., & Ofori, A. D. (2024) · SPEKTA (Jurnal Pengabdian Kepada Masyarakat Teknologi dan Aplikasi) · doi:10.12928/spekta.v5i2.8994
“One aspect of healthcare that has proven to be very problematic for many individuals is the accessibility of medications [3] .”
Bassoum, O., Fuller, W. L., Camara, M. D., Sow, A., Ndiaye, N., Lèye, M. M. M., & Seck, I. (2025) · Central African Journal of Public Health · doi:10.11648/j.cajph.20251101.13
Youth Should Be Part of African Pharma Industry—A Perspective
Inshutiyimana, S. (2025) · Health Science Reports · doi:10.1002/hsr2.70683
Accuracy of self-screening tools for contraindicated use of oral contraceptives: A systematic review
Beheshti, F., Nyrann, S., Løkkegaard, E., & Carlsen, S. E. (2025) · Danish Journal of Obstetrics and Gynaecology · doi:10.56182/he0dke50
Conformance to the National List of Essential Medicines 2022 in a government tertiary care hospital
Jain, A., Bhardwaj, N. D., Suhaib, M., Srivastava, P., Khan, S., & Rawat, S. (2025) · Journal of Healthcare Quality Research · doi:10.1016/j.jhqr.2025.101141
Zhao, M., Lin, C., Ding, S., Han, Y., Zhao, Y., Gillani, A. H., & Fang, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1555598
BHATNAGAR, S., & KUMAR, D. V. (2025) · International Journal of Environmental Sciences · doi:10.64252/0k9evy45
Shovo, T.-E.-A. (2025) · Khulna University Studies · doi:10.53808/kus.2025.22.01.1375-ss
Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)
Badheeb, A. M., Munjem, M. F. A., Ahmed, F., Aljedaani, H., Assiri, N., Abdulaziz, A., Abubakar, A., AlQurayshah, M., & Badheeb, M. A. (2025) · F1000Research · doi:10.12688/f1000research.147910.2
Kokane, A. M., Pakhare, A. P., Vantepaka, S., & Ananthakrishnan, M. (2025) · Journal of Hunger & Environmental Nutrition · doi:10.1080/19320248.2025.2554240
“13,14 Another significant barrier was the lack of financial incentives for AWWs, who expressed dissatisfaction with the absence of additional compensation for the extra responsibilities related to CSAM.”
A Vicious Cycle of Access to Excluded Medicines: Evidence from a Qualitative Study
Çapar, H. (2025) · İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi · doi:10.38079/igusabder.1673550
Bhattacharya, S., Singh, A. P., Majhi, L., Sarkar, D., & Singh, A. (2025) · Research Square · doi:10.21203/rs.3.rs-7609839/v1
Optimization of pharmaceutical supply chain operations
Heydari, J., & Tat, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28993-4.00222-5
Nagitta, O. P., Mkansi, M., & Kajjumba, G. W. (2025) · The Journal of Medicine Access · doi:10.1177/27550834251378933
“Yenet et al. 37 emphasized the importance of strong coordination among market actors to maintain a consistent medicine supply.”
Shedul, G. J., Ugwuneji, E. N., Jamro-Comer, E., Banigbe, B., Ponzing, P., Okpe, I., Ripiye, N. R., Orji, I. A., Shedul, G. L., Osagie, S., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018029 · Cited by 3
Mapping the social networks of key actors in the development of health technology assessment in IranPreprint
Behzadifar, M., Bakhtiari, A., Azari, S., Shahabi, S., Martini, M., Saran, M., Ehsanzadeh, S. J., & Behzadifar, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5039231/v1
Meyer, O., Ruiz, R., Wu, L., Young, M., John, A., Famolari, K., Kuzma, V., Angle, M., Obeysekare, E., & Mehta, K. (2025) · IEEE Global Humanitarian Technology Conference (GHTC) · doi:10.1109/ghtc66843.2025.11266433
Slamang, W., Scott, C., & Foster, H. (2024) · Figshare · doi:10.6084/m9.figshare.26743469
Afifi, M., Hemachandra, N. N., Sikandar, Q., Hajjeh, R. A., Loi, U. R., Läser, L., Qato, D., Abdul, Z. S., Chikvaidze, P., Abbas, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26729575
Slamang, W., Scott, C., & Foster, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.26743466
Batlhophi, M. G., Bwacha, F., Phirinyane, B. S., Tibe, O., Molojwane, E., Kobue-Lekalake, R. I., Matenanga, O. K., Sekwati‐Monang, B., Bultosa, G., Seifu, E., et al. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.1312030
Tolossa, T., Gold, L. H., Lau, E. H. Y., Dheresa, M., & Abimanyi-Ochom, J. (2025) · BMC Public Health · doi:10.1186/s12889-025-26091-9
“These expenses can lead to delayed or reduced ANC visits, compromised nutrition, or skipped medications, all of which increase the risk of LBW [71].”
Kengia, J. T., Lyimo, V. O., Gibore, N. S., Nicas, L., Kagoma, P., Ngowi, J. E., Mshana, D., Mageda, K., Jiyenze, M. K., Kikula, A. I., et al. (2025) · Pan African Medical Journal · doi:10.11604/pamj.supp.2025.52.1.46896
Beyond Affordability: Trust, Sustainability, and the Lived Experiences of Jan Aushadhi Kendra Owners
Aboobaker, N., & Dr. Priya, R. (2026) · International Journal of Latest Technology in Engineering Management & Applied Science · doi:10.51583/ijltemas.2026.150100042
Igirikwayo, Z. K., Mukaga, H., & Migisha, R. (2026) · Discover Public Health · doi:10.1186/s12982-026-01425-z · Cited by 1
“Medicines are a cornerstone of healthcare systems and represent a substantial portion of national budgets, accounting for up to 10–20% in developed nations and 20–40% in developing nations [2].”
Andrei, T., Mirică, A., & Stoica, I.-E. (2025) · Journal of Social and Economic Statistics · doi:10.2478/jses-2025-0006
“This applies even to essential medicines, namely, those vital for preserving human life (Yenet et al., 2023).”
Belayneh, A., Getachew, M., Abebe, D., Gashaw, M., Nibret, G., Ayenew, T., & Dessie, B. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03227
Self-citationObakiro, S. B., Kibuuka, R., Nakazibwe, B., Kanyike, A. M., Mawejje, F., Namugaya, M., Muwanga, S. N., Maseruka, R., Nabitandikwa, C., Kiyimba, K., et al. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14145-6
“About half of the population in sub-Saharan Africa including Uganda continue to face significant barriers to obtaining essential medicines [6].”
Gonah, L., Nomatshila, S. C., Mabunda, S. A., & Chitha, W. W. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23020215
“Mean stock-out durations were categorized as low ( ≤ 3 days per month), moderate (4–6 days), and prolonged ( ≥ 7 days), consistent with previous studies on medicine availability in LMIC settings [8,18,19].”
Katabalo, D. M., Chuwa, J., Mwita, S. M., Liwa, A. C., Kidenya, B. R., & Schroeder, K. (2026) · Journal of Pediatric Hematology/Oncology Nursing · doi:10.1177/27527530251398467
“The most prominent challenge identi fi ed in their research is insuf fi cient funding to cover a necessary range of essential medications, which make up a large share of household expenses (Yenet et al., 2023).”
Belachew, M. D., LACHORE, W. L., SAKA, S. F., ASSEFA, A., & Marew, T. (2025) · AFRICAN JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT · doi:10.59493/ajopred/2025.3.3
Mwebaza, L. J., Mpamize, H., Nansereko, H., Naggulu, I. P., Ssemuwemba, F., & Nalubega, J. F. (2026) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v7i3.2273
Haabazoka, L., & Lole, M. (2026) · Science Mundi · doi:10.51867/scimundi.6.1.17
Tarrafeta-Sayas, M.-B., Rerat, C., Pilon, S., Rakotonarivo, M. V., Koukpemedji, L., Yapo, S., Duncan, R., Hodjo, D., Baki, L. S., Minoungou, A., et al. (2026) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2026.2649302
“…planning capacity and financial constraints at the facility level can cause inconsistent orders and misalignment with real needs, while inadequate prescribing practices may further distort demand data (Aderaw Yenet et al., 2023; Kaupa et al., 2021; Ravinetto et al., 2024; Shukar et al., 2021).”
Nyarko, K. M., Totah, T., Akyereko, E., Barry, A., Farham, B. L., & Impouma, B. (2026) · International Journal of Noncommunicable Diseases · doi:10.4103/jncd.jncd_31_26
Mwebaza, L. J., Mpamize, H., Nansereko, H., Naggulu, I. P., Ssemuwemba, F., & Nalubega, J. F. (2026) · doi:10.70572/agp.v3i1.120
Accessibility of Biologic Drugs in Morocco: Comparison with FDA and EMA Approvals (2015–2025)
Charrak, M., Cherrah, Y., & Serragui, S. (2026) · Journal of Market Access & Health Policy · doi:10.3390/jmahp14020021
Esmaeili, S. V., Shafagh, H., Feyzi, V., & Pouyakian, M. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14556-5
“In contrast, pharmacies in develop‑ ing countries tend to focus on the provision of essential medicines and basic services and face challenges such as resource scarcity and limited access to information [5, 6].”
Marew, T., Belete, A., RICHMOND, F. J. R., & Gebre‐Mariam, T. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261442037
“7,8 The work of the NRAs is complicated by the fast pace of scientific advances, increasing complexities of healthcare technologies and evolving regulatory requirements.”
Accrombessi, M., Esch, K., Woolheater, K., Wang, E., Bouanchaud, P., & ACTwatch Lite Group (2026) · doi:10.12688/verixiv.3131.1
Chomini, S. (2025) · KIU journal of science engineering and technology · doi:10.59568/kjset-2025-4-2-18
Шамилевна, Г. Ю., & Abramov, A. U. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.325
The High Cost of Inexpensive Medicines
Blewusi, G., Zheng, R., Gaayeb, L., & Flexner, C. W. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70216
Sawan, E. S., Mostafa, M., Sayed, Y. T., Binsaleh, A. Y., MOHAMED, M. A., & Hussein, R. R. S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1847196
“In these regions, persistent concerns regarding the quality and reliability of generic drugs can lead to a continued preference for brand drugs among healthcare professionals, including pharmacists, despite the lower cost of generics (Yenet et al., 2023; Calamia and Abraham, 2023).”
Osayi, E. E., Urama, D. C., Amujiri, A. N., Agyo, R. A., Afyare, A. A. A., & Andong, F. A. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-026-05426-y
“Limited access to affordable healthcare, high personal healthcare costs and uneven distribution of medical facilities remain persistent challenges in many low and middle income countries [1].”
Ahmed, M. A. A., Konta, M., Coulibaly, I., Diarra, D., Alami, H., Kielmann, K., & Ravinetto, R. (2026) · Global Health Action · doi:10.1080/16549716.2026.2676369
“These are observed also in politically stable low-resource settings, with frequent shortages and stock-outs, caused by poor stock management and limited super-vision [48–50].”
Obomanu, E., Ugwu, C. J., Megiso, M. Z., Verinumbe, T. I., Jones, C., Vanderpuye, V. D. N. K., & Hammad, N. (2026) · JCO Global Oncology · doi:10.1200/go-25-00692
Darko, G., Sadari, P., Quarshie, D., Agyekum, G. A., Salifu, Y., Odonkor, F. O., & Boateng, K. S. (2026) · BMC Public Health · doi:10.1186/s12889-026-28131-4
“This substantial cost burden contributes to treatment interruption and non-adherence, consistent with evidence from other chronic disease management studies in low-resource settings [56, 57].”
Ndwandwe, M. M., Lowane, M. P., Simbeni, T. V., & Mokgatle, M. M. (2026) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v18i1.5356
Kirika, R., Onyango, J. O., & Orwa, J. (2026) · International May Conference on Strategic Management (IMCSM) · doi:10.5937/imcsm26226k
Intellectual Property Rights: Policy Issues in the International Context
Wellington, A. (2026) · Springer eBooks · doi:10.1007/978-3-642-27828-0_10072-1
Jayakumar, B., Muthahanumaiah, N. M. K., Thimmegouda, N., & Reddy, P. P. K. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20261958
Marew, T., Belete, A., RICHMOND, F. J. R., & Gebre‐Mariam, T. (2026) · Tropical Medicine and Health · doi:10.1186/s41182-026-01009-2
“In addition, other studies have highlighted fragmented regulatory requirements and procedures as major barriers to the registration and supply of medicines in African countries [73, 74].”
Abebe, T. B., Alemayehu, T. T., Demelash, T. M., Asefa, H. Y., Yferu, Z. A., Sebsebe, L. W., Tilahun, R. D., Mengestu, W. N., Fikru, M. G., Gurmu, N. T., et al. (2026) · Global Health Research and Policy · doi:10.1016/j.ghrp.2026.06.007
“67 No-tably, adherence rates varied widely across studies (1.1–88.4%), high-lighting the complex interplay of contributing factors and the need for deeper investigation—a pattern also observed in Middle Eastern studies.”
InfluentialRahmansyah, R., Mujahid, M., Arief, A. S., & Riyadi, S. (2025) · Journal Development Manecos · doi:10.71435/738357
Yasmin, S., Mansuri, R., Ashique, S., Das, J., Hussain, M. S., & Ansari, M. Y. (2026) · Next research. · doi:10.1016/j.nexres.2026.102106
Mwansa, A. B., & Mudenda, S. (2026) · Open Journal of Business and Management · doi:10.4236/ojbm.2026.144107
Sabola, S., Phiri, M. M., Nyirenda, D., Msefula, C. L., Mwendera, C. A., Cunliffe, N. A., & Osman, R. (2026) · Journal of Global Health Economics and Policy · doi:10.7189/001c.164740
Mengesha, M., Gujo, A. B., Dona, A., & Yote, N. Y. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261468783
“37 Furthermore, perceived long length of stay in the hospital negatively affected patients’ satisfaction in this study.”
Behzadi, A., Fatahpour, A., Ghobadi, M., & Amiresmaili, M. (2026) · International Journal for Equity in Health · doi:10.1186/s12939-026-02948-2 · Cited by 1
“However, in many health systems—particularly in low-and middle-income coun-tries—the implementation of such reforms has been accompanied by substantial financial, institutional, and governance-related challenges [1–3].”
Ugwu, L. E., Basil, B., Ugwoke, U. F., Kamanga, E. H., & Okoro, N. I. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006306
“Several explanations are plausible, including inconsistent medication availability, episodic follow-up, suboptimal titration, and adherence barriers [12,13].”
Marcolino, M. S., da Costa, M. R., Schettini, I. V. G., Dalakoti, M., Liu, H., & Njohjam, M. N. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20250286
Abuko, L. K., & Okonda, M. W. (2026) · International journal of research and scientific innovation · doi:10.51244/ijrsi.2026.1307000017
Aguiyi-Ikeanyi, C., Osahon, P. T., & Udezi, W. (2026) · African Journal of Health Economics · doi:10.35202/ajhe.2026.16101
Healthguider: A Master Healthcare Supply Chain File and Database System
Matenda, F. R., Mkansi, M., & Saliwe, P. (2026) · Springer series in supply chain management · doi:10.1007/978-3-032-20501-8_6
Alcock, S., Beukes, J., Hart, C., Scheuermaier, K. D., Lye, S. J., & Norris, S. A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00146-z
“…the consistently low loading of sleep medication use across all models likely reflects contextual factors, including limitations in the availability and affordability of prescription medications [56, 57] and a lack of awareness that poor sleep quality is a concern requiring further treatment [28].”
Adigwe, O. P., Onavbavba, G., Alabi, T. F., & Uzuh, N. R. (2026) · Health Science Reports · doi:10.1002/hsr2.72624
“In Africa, the situation is exacerbated by inadequate funding, the prevalence of counterfeit medicines, and supply chains that are highly reliant on imports [8].”
Mageto, J., Tlholwe, M., & van den Berg, H. (2026) · Logistics · doi:10.3390/logistics10080187
“One primary issue is the inconsistent availability of essential items due to inefficient inventory management and limited tracking capabilities [44].”
Okello, F. O., Engebretsen, I. M. S., Olupot‐Olupot, P., Tylleskär, T., & Medina‐Lara, A. (2026) · Research Square · doi:10.21203/rs.3.rs-10541179/v1
Global burden of viral infections and promise of botanical antivirals
Fongang, H., Mbaveng, A. T., & Kuete, V. (2026) · Advances in botanical research · doi:10.1016/bs.abr.2026.07.019
Assefa, A. N., Dagnew, F. N., Alemu, M. A., Kassie, A. B., & Yimer, Y. S. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100832
“18,36 In the Amhara region, the ongoing socioeconomic challenges, including inflation, conflict-related disruptions, population displacement, and interruptions in healthcare services, may further amplify these financial pressures.”
Rispel, L. C., Ditlopo, P., & Blaauw, D. (2026) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzag124
Njiru, M. M., Ndege, S., Owiny, M. O., Diero, L. O., & Humphrey, J. M. (2026) · AIDS Care · doi:10.1080/09540121.2026.2728207
Metadata
- Authors
- Yenet, A., Nibret, G., & Tegegne, B. A.
- Affiliations
- Debre Markos University (ET)
- Corresponding author
- Yenet, Aderaw
- Nibret, Getinet
- Tegegne, Bantayehu Addis
- Venue
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2023-06
- Volume
- Volume 15
- Pages
- 443-458
- ISSN
- 1178-6981 (ISSN-L)
- PMC
- PMC10276598
- OpenAlex
- W4380630724
- Semantic Scholar
- ac3ee2843ccf5f72c24e512e988b5d506ce6a96a
- Cited by
- 202
- References
- 22
- Citations by year
- 2026: 83 · 2025: 73 · 2024: 43 · 2023: 3
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- essential medicines, drug availability, drug affordability, Africa, health care financing, drug pricing, inventory management, drug registration, intellectual property, health workforce shortage, household health expenditure, right to health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

